Angelica Sinensis Polysaccharide-Based Nanoparticles for Liver-Targeted Delivery of Oridonin.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, c1995-

Carcinoma, Hepatocellular*/drug therapy ; Carcinoma, Hepatocellular*/pathology ; Angelica sinensis* ; Desoxycorticosterone Acetate* ; Liver Neoplasms*/drug therapy ; Nanoparticles*/chemistry ; Diterpenes, Kaurane*; Mice ; Animals ; Drug Carriers/chemistry ; Polysaccharides/therapeutic use

The present work aimed to study the feasibility of Angelica sinensis polysaccharide (ASP) as an instinctive liver targeting drug delivery carrier for oridonin (ORI) in the treatment of hepatocellular carcinoma (HCC). ASP was reacted with deoxycholic acid (DOCA) via an esterification reaction to form an ASP-DOCA conjugate. ORI-loaded ASP-DOCA nanoparticles (ORI/ASP-DOCA NPs) were prepared by the thin-film water method, and their size was about 195 nm in aqueous solution. ORI/ASP-DOCA NPs had a drug loading capacity of up to 9.2%. The release of ORI in ORI/ASP-DOCA NPs was pH-dependent, resulting in rapid decomposition and accelerated drug release at acidic pH. ORI/ASP-DOCA NPs significantly enhanced the accumulation of ORI in liver tumors through ASGPR-mediated endocytosis. In vitro results showed that ORI/ASP-DOCA NPs increased cell uptake and apoptosis in HepG2 cells, and in vivo results showed that ORI/ASP-DOCA NPs caused effective tumor suppression in H22 tumor-bearing mice compared with free ORI. In short, ORI/ASP-DOCA NPs might be a simple, feasible, safe and effective ORI nano-drug delivery system that could be used for the targeted delivery and treatment of liver tumors.

Int J Nanomedicine. 2019 Aug 29;14:6971-6988. (PMID: 31507319)
Bioconjug Chem. 2021 Apr 21;32(4):763-781. (PMID: 33691403)
Drug Deliv Transl Res. 2023 Oct;13(10):2463-2474. (PMID: 37010791)
Molecules. 2020 Jan 14;25(2):. (PMID: 31947574)
Int J Biol Macromol. 2021 Jul 31;183:2337-2353. (PMID: 34090852)
Chin J Nat Med. 2013 Nov;11(6):577-87. (PMID: 24345498)
J Adv Res. 2023 Jul;49:159-173. (PMID: 36167294)
Glycoconj J. 2016 Oct;33(5):755-61. (PMID: 27129881)
Drug Deliv. 2022 Dec;29(1):2044-2057. (PMID: 35775475)
J Biomater Appl. 2017 Mar;31(8):1182-1195. (PMID: 28081668)
Lancet. 2022 Oct 15;400(10360):1345-1362. (PMID: 36084663)
ACS Appl Mater Interfaces. 2023 Jun 7;15(22):26298-26315. (PMID: 37233992)
Artif Cells Nanomed Biotechnol. 2018;46(sup1):254-263. (PMID: 29291632)
Colloids Surf B Biointerfaces. 2016 Nov 1;147:90-99. (PMID: 27497073)
Drug Deliv. 2021 Dec;28(1):2071-2084. (PMID: 34595970)
Biosci Trends. 2021 Jul 6;15(3):138-141. (PMID: 33746184)
Carbohydr Polym. 2017 Mar 1;159:178-187. (PMID: 28038747)
Int J Pharm. 2014 Nov 20;475(1-2):60-8. (PMID: 25152167)
Oncol Rep. 2017 Aug;38(2):819-828. (PMID: 28677813)
Int J Biol Macromol. 2010 Nov 1;47(4):546-50. (PMID: 20691723)
Clin Liver Dis. 2023 Feb;27(1):85-102. (PMID: 36400469)
Food Funct. 2018 Mar 1;9(3):1829-1839. (PMID: 29517797)
Carbohydr Polym. 2019 Jun 1;213:17-26. (PMID: 30879657)
Hong Kong Med J. 2022 Dec;28 Suppl 6(6):10-11. (PMID: 36535791)
Phytomedicine. 2021 Jan;80:153356. (PMID: 33039729)
Klin Onkol. 2020 Fall;33(Supplementum 3):26-29. (PMID: 33213162)
Recent Pat Anticancer Drug Discov. 2020;15(4):341-359. (PMID: 33023456)
ACS Biomater Sci Eng. 2021 Aug 9;7(8):3764-3773. (PMID: 34213326)
Front Pharmacol. 2019 Jul 12;10:769. (PMID: 31354485)
Int J Pharm. 2020 Jun 15;583:119351. (PMID: 32339634)
Chembiochem. 2016 Apr 1;17(7):590-4. (PMID: 26781030)
Drug Deliv. 2022 Dec;29(1):138-148. (PMID: 34967268)
Carbohydr Polym. 2019 Sep 1;219:143-154. (PMID: 31151511)
J Control Release. 2015 Apr 10;203:126-39. (PMID: 25701309)
Sci Rep. 2020 Sep 16;10(1):15199. (PMID: 32939004)
Int J Biol Macromol. 2019 Oct 15;139:665-677. (PMID: 31377298)
Nanoscale. 2018 Apr 19;10(15):7108-7115. (PMID: 29616243)
J Ultrasound Med. 2024 Jan;43(1):95-107. (PMID: 37815381)
Phys Biol. 2016 May 11;13(3):031001. (PMID: 27172135)
Anal Sci. 2005 Oct;21(10):1177-80. (PMID: 16270574)
Molecules. 2008 Oct 01;13(10):2408-15. (PMID: 18830163)
Phytother Res. 2023 May;37(5):2187-2211. (PMID: 37086188)
J Drug Target. 2022 Mar;30(3):287-301. (PMID: 34727794)
Biomacromolecules. 2023 Mar 13;24(3):1274-1286. (PMID: 36780314)
JAMA Surg. 2023 Apr 1;158(4):410-420. (PMID: 36790767)

ZR2022MH173 Shandong Provincial Natural Science Foundation, China; 202113020512 the Medical and Health Science and Technology Development Plan of Shandong Province, China

Keywords: Angelica sinensis polysaccharide; antitumor; drug delivery; nano-carrier; oridonin; pH-sensitive

0APJ98UCLQ (oridonin)
6E0A168OB8 (Desoxycorticosterone Acetate)
0 (Drug Carriers)
0 (Polysaccharides)
0 (Diterpenes, Kaurane)

Date Created: 20240210 Date Completed: 20240214 Latest Revision: 20240214

20240214

PMC10856552

10.3390/molecules29030731

38338476